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Abstract 
This paper presents the results of bioinformatic 
analysis of three polymorphic loci in 170 women who 
suffer from a combination of uterine fibroids with 
endometrium hyperplastic processes and in 981 
women of the control group without proliferative 
diseases of pelvic organs. It was found that the 
combinations of molecular genetic markers С 
rs673220, А rs4986938 и G rs887912 (ОR=1.70) are 
risk factors for the development of a combination of 
endometrial hyperplasia and uterine myoma among 
women of the Central region of Russia. 
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Introduction 
Among the gynecological incidence, the hyperplastic 
processes of the endometrium occupy a leading place 
and amount to 10-50% [Boyraz G. et al., 2016]. 
Endometrial hyperplasia is a pathological process 
affecting the epithelial and stromal components of the 
endometrium and is manifested by an increase in the 
total number of glands [Clement N.S. et al., 2016]. 
Atypical endometrial hyperplasia is a precancerous 
condition, which can cause the development of 
endometrial cancer in 15-45% of cases [Kadirogullari 
P. et al., 2015]. The risk of development of 
endometrial cancer in women increases significantly 
with age and ranges from 5 to 10% [Kim M.-J. et al., 
2016]. 
Uterine myoma is a benign monoclonal tumor 
composed of the smooth muscle cells of the 
myometrium. The prevalence of uterine fibroids 
ranges from 5% to 65%, depending on age, ethnicity, 
geographic region and diagnostic method [Gurusamy 
K.S. et al., 2016]. According to the literature, uterine 
fibroids are most often observed in women of 
reproductive age (about 40%) [Khan A.T. et al., 2014] 
and reaches a peak at 50 years [Zimmermann A. et al., 
2012]. According to various data, surgical 
interventions are performed in 25-50% of women 
diagnosed with uterine myoma [Gurusamy K.S. et al., 
2016]. 
According to literature data, the combination of 
endometrial hyperplasia with uterine myoma occurs in 
30-35% of patients, due to the common etiology, risk 
factors and key pathogenetic links [Tan N. et al., 
2014]. The well-known risk factors for the 
development of proliferative diseases of the uterus 
include age, early menarche, late menopause, absence 
of pregnancy in history, obesity, diabetes, family 
history, lifestyle, etc. [Segars J.H. et al., 2014; 
Chandra V. et al., 2016]. The leading premium in the 
etiopathogenesis of hyperplastic processes of the 
endometrium and uterine myoma is set on excessive 
estrogen stimulation, hormone-independent 
proliferation, inflammation, reduced apoptosis, 
pathological neoangiogenesis, and cytogenetic 
disorders [Segars J.H. et al., 2014; Chandra V. et al., 
2016]. 
The combined development of these diseases is of 
great clinical importance, since it raises significant 
difficulties in diagnosing and choosing the most 
effective method of treatment. In addition, it leads to a 
decrease in the quality of life of a woman. 
Now it is known that polymorphisms of several genes 
are important in the formation of disposition to the 
development of hyperplastic diseases of uterus 
[Edwards T.L. et al., 2013; Krivoshei I.V. et al., 2015; 
Orbo A. et al., 2016; Pachomov S.P. et al., 2016; 
Ponomarenko, I.V. et al., 2016]. However, the results 
of studies on the role of candidate genes in the 
formation of hyperplastic processes of the 
endometrium and uterine myoma are controversial in 
different populations.  
Objective of the research was a bioinformatic study of 
the involvement of three genetic polymorphisms 
(rs887912, rs6732220, rs4986938) in the development 
of a combination of endometrium hyperplastic 
processes with uterine myoma in women of the 
Central region of Russia. 
 
Materials and Methods 
In this study, patients with a combination of uterine 
myoma and endometrial hyperplasia (n=170) were 
selected from a group of 947 patients with various 
uterine hyperplastic processes. The sample was made 
on the basis of the gynecological department of the 
perinatal center of St. Joasaph Belgorod Regional 
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Clinical Hospital. Patients with a combination of 
uterine myoma and endometrial hyperplasia 
underwent a clinical, clinical and laboratory 
examination, ultrasound examination of pelvic organs, 
hysteroscopy followed by targeted diagnostic scraping 
of the uterine cavity and histological examination of 
scrapings. All patients signed an informed consent for 
inclusion in the study and use of the data obtained. The 
control group involved 981 women without 
proliferative diseases of the pelvic organs. 
All patients with endometrial hyperplasia and uterine 
myoma were performed typing of three molecular-
genetic markers rs887912 FLJ30838, rs6732220 
FSHR, rs4986938 ESR2. The choice of these 
polymorphic markers for the study is due to their 
significant regulatory and expression potential 
(HaploReg (v.4.1.) 
(http://compbio.mit.edu/HaploReg)) and the 
important ethiopathogenetic significance of these 
genes for hyperplastic uterine disease [Commandeur 
A.E. et al., 2015]. 
As the material for the study we used 8-9 ml of venous 
blood taken from the cubital vein of a proband. A 
genomic DNA was isolated from peripheral blood by 
the method of phenol-chloroform extraction (Mathew 
C.G., 1985). Analysis of the investigated loci was 
carried out by the method of polymerase chain 
reaction of DNA synthesis with the use of 
oligonucleotide primers and probes. 
Statistical processing of data was carried out using 
STATISTICA for Windows 6.0 and Microsoft Excel 
2007 software packages. To analyze the compliance of 
the observed distribution of genotypes with the 
expected one, based on Hardy-Weinberg equilibrium, 
we used 2 test. 
A bioinformatic study was performed by APSampler 
[http://sources.redhat.com/cygwin/], operating 
Markov chain Monte Carlo, and Bayesian 
nonparametric statistics [Favorov A., 2011]. 
 
Results and Discussion 
We examined 170 female patients with the 
combination of uterine myoma and endometrial 
hyperplasia, and 981 women of the control group. The 
main characteristics of the study and control groups 
are shown in Table 1. The control group is fully 
comparable to the sample of patients with the 
combination of uterine myoma and endometrial 
hyperplasia by age, ethnicity, and place of birth. 
Characteristics Cases Controls 
Total 170 981 
Age, yrs  45.06±8.23 39.94±9.31 
Height, cm 1.66±0.07 1.65±0.06 
Weight, kg 77.09±14.50 69.69±12.49 
IMB 28.10±5.80 25.69±4.24 
Table 1 Characteristics of the Subjects from the 
Case and Control Groups. 
The analysis of the distribution of studied polymorphic 
markers of candidate genes showed that for all the 
studied loci in the group of patients with the 
combination of uterine myoma and endometrium 
hyperplastic processes, as well as in the control 
sample, the empirical distribution of genotypes 
corresponds to the theoretically expected one at 
Hardy-Weinberg equilibrium (p>0.05).  
As a result of the bioinformatic analysis, significant 
differences in the concentrations of C alleles rs673220 
with А rs4986938 with G rs887912 were found among 
the patients with a combination of endometrial 
hyperplasia and uterine myoma (62.87%) and the 
control group (49.84%). This combination of allelic 
variants is a risk factor for the development of 
endometrial hyperplasia and uterine myoma (p=0.001, 
pperm = 0.011, OR=1.70, 95% CI 1.21-2.39).  
Using HaploReg (v.4.1.) online service 
(http://compbio.mit.edu/HaploReg), the regulatory 
potential and the influence on the expression of genes 
of significant polymorphisms associated with the 
combination of endometrial hyperplasia and uterine 
myoma were studied. The genetic polymorphism 
rs6732220, localized in the intron portion of the FHSR 
gene, affects the transcription activity of this gene in 
the testes (p=2.81E-08). It participates in the 
development of menarche age (p=0.0018) 
[Lappalainen T. et al., 2013]. 
The genetic polymorphism rs887912, located 12 kb 
from the 3’ end of the FLJ30838 gene has a high 
regulatory and expressive potential and marks histone 
proteins within the enhancers. It should be noted that 
G allele (as part of the three combinations increases 
the risk of hyperplastic processes of the endothelium 
and uterine myoma) increases the affinity of the DNA 
motif - Hoxa5_1 (PWM = -0.6), while its reference A 
allele is associated with increased affinity of the 
Znf143_known1 motif (PWM=1.0). This genetic 
polymorphism is associated with a body mass index 
(p=2E-22) [Speliotes E.K. et al., 2010] and 
anthropometric characteristics at pubertal age (p=1E-
10) [Berndt S.I. et al., 2013] and the age of menarche 
[Fernandez-Rhodez L. et al., 2013]. 
The polymorphic locus rs4986938, located in 3’ of the 
end of the ESR2 gene, marks histone proteins in the 
region of promoters in the cerebral cortex and blood 
cells. It affects the expression level of the ESR2 gene 
in the left ventricle of the heart (p=9.99Е-07), skin 
cells (р=3.86Е-08) [Ardlie K.G. et al., 2015]  and 
lymphoblast cells (p=3.65E-10) [Lappalainen T. et al., 
2013]. It should be noted that this gene is most actively 
expressed in testes (RPKM: 1.79±0.27), adrenal 
glands (RPKM: 1.09±0.28), ovaries (RPKM: 
0.60±0.09), lymph nodes (RPKM: 0.42±0.21), adipose 
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tissue (RPKM: 0.48±0.04). This genetic 
polymorphism is part of five DNA motifs. At the same 
time, the "risky" A allele increases the affinity of the 
regulatory motif CTCF_known1 (PWM=0.6), Pax-
6_1 (PWM=11.1), RAR (PWM=0.1).  
 
Conclusion 
Thus, the results of the study allow us to conclude that 
the combinations of molecular genetic markers С 
rs673220, А rs4986938 и G rs887912 (ОR=1.70) are 
risk factors for the development of a combination of 
endometrial hyperplasia and uterine myoma among 
women of the Central region of Russia. 
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